Can Fetuin-A Be a Marker for Insulin Resistance and Poor Glycemic Control in Children with Type 1 Diabetes Mellitus?

J Clin Res Pediatr Endocrinol. 2017 Dec 15;9(4):293-299. doi: 10.4274/jcrpe.4532. Epub 2017 May 22.

Abstract

Objective: Metabolic impairment in type 1 diabetes mellitus (T1DM) with poor glycemic control causes insulin resistance, non-alcoholic fatty liver disease (NAFLD), atherosclerosis, and increased carotid intima-media thickness (CIMT). Fetuin-A has a protective effect in cardiovascular disorders and is increased in hepatosteatosis. We aimed to investigate the reliability of fetuin-A levels in early detection of diabetic complications in children with T1DM and to identify a cut-off value that may show poor metabolic control.

Methods: The study included 80 patients who had T1DM for at least 5 years and who had no chronic complications or an auto-immune disorder. Blood samples were drawn to measure hemoglobin A1c (HbA1c), biochemical parameters, and fetuin-A levels. Anthropometric parameters were also measured. Percent body fat was calculated. Hepatosteatosis and CIMT were assessed by sonography.

Results: Mean age of the patients was 13.5 years. Grade 1 hepatosteatosis was detected in 10%. Patients were stratified into 2 groups based on presence of NAFLD. Fetuin-A level was increased in patients with NAFLD. We identified a fetuin-A cut-off value (514.28 ng/mL; sensitivity: 47.34; specificity: 96.72) that may predict NAFLD. HbA1c and total cholesterol levels were found to be higher in patients with fetuin-A levels above higher the cut-off value.

Conclusion: Fetuin-A is a reliable parameter in the prediction of complications and poor glycemic control in patients with T1DM.

Keywords: Non-alcoholic fatty liver disease; fetuin-a; type 1 diabetes mellitus complication..

MeSH terms

  • Adolescent
  • Atherosclerosis / blood
  • Atherosclerosis / complications
  • Biomarkers / analysis*
  • Biomarkers / metabolism
  • Blood Glucose / metabolism*
  • Case-Control Studies
  • Child
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / complications*
  • Diabetes Mellitus, Type 1 / diagnosis*
  • Diabetes Mellitus, Type 1 / therapy
  • Female
  • Humans
  • Insulin Resistance*
  • Male
  • Non-alcoholic Fatty Liver Disease / blood
  • Non-alcoholic Fatty Liver Disease / complications
  • Prognosis
  • Reproducibility of Results
  • Treatment Failure
  • alpha-2-HS-Glycoprotein / analysis*
  • alpha-2-HS-Glycoprotein / metabolism

Substances

  • Biomarkers
  • Blood Glucose
  • alpha-2-HS-Glycoprotein